CAR-T Therapies for Aggressive Large Cell Lymphoma Age ≥ 18 Yrs

CAR Therapies following prior CAR Therapy

Expanded Access protocols for commercial CAR-T products manufactured of specification

CCT5006 Expanded Access Anti-CD19 Chimeric Antigen Receptor T-Cells (CAR-T Cells) in Relapsed/Refractory B-Cell Lymphomas
- PI: Miklos Sponsor: Azadlab, Inc.

CCT5016 Managed Access Program (MAP) CTL019 in ALL or DLBCL
- PI: Miklos Sponsor: Novartis

CCT5034 EAP for Patients Receiving Anti-CD20 Maralixibat That is Non-conforming for Commercial Release
- PI: Miklos Sponsor: Juno Therapeutics, Inc.

CCT5044 Phase II/III trial of Bi-specific CD19 & CD22 CAR-T
- PI: Parveen Sponsor: Kite Pharma

CCT5036 Phase II Anti-CD30 Anti-CD19 Specific Chimeric Antigen Receptor in Relapsed and Refractory Large B-Cell Lymphoma
- PI: Parveen Sponsor: Kite Pharma

CCT5032 Phase II/III Anti-CD19 & Anti-CD20 Specific Chimeric Antigen Receptor in Relapsed and Refractory Large B-Cell Lymphoma
- PI: Miklos Sponsor: Stanford

CCT5045 3rd line CAR Therapies

Age < 65 Yrs

CCT5046 Phase I/II trial of Bi-specific CD19 & CD20 CAR-T
- PI: Miklos Sponsor: Pending

CCT5042 Pilot 18F-FAAT PET Imaging to Evaluate Immunological Response to CAR T Cell Therapy in Lymphoma
- PI: Miklos Sponsor: Stanford

Age > 65 Yrs

CCT5038

KEY

<table>
<thead>
<tr>
<th>Status</th>
<th>Icon</th>
<th>Legend</th>
</tr>
</thead>
<tbody>
<tr>
<td>Pending</td>
<td>Grey square</td>
<td></td>
</tr>
<tr>
<td>Open for Enrollment</td>
<td>Light blue square</td>
<td></td>
</tr>
<tr>
<td>Observational Study</td>
<td>Dark grey square</td>
<td></td>
</tr>
<tr>
<td>Enrollment on Hold</td>
<td>Yellow square</td>
<td></td>
</tr>
<tr>
<td>Optional Path</td>
<td>Link</td>
<td></td>
</tr>
<tr>
<td>Trial Posting</td>
<td>Grey triangle</td>
<td></td>
</tr>
<tr>
<td>Extension Study</td>
<td>Diamond</td>
<td></td>
</tr>
<tr>
<td>Immunotherapy</td>
<td>Circle with cross</td>
<td></td>
</tr>
</tbody>
</table>